Diego O Croci Selected Research

1-nitrohydroxyphenyl-N-benzoylalanine (GAL 1)

1/2021	Characterization of a neutralizing anti-human galectin-1 monoclonal antibody with angioregulatory and immunomodulatory activities.
1/2021	Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8+ regulatory T cells.
11/2014	Targeting galectin-1-induced angiogenesis mitigates the severity of endometriosis.
1/2013	A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.
10/2012	Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma.
7/2012	Binding of galectin-1 to αIIbβ₃ integrin triggers "outside-in" signals, stimulates platelet activation, and controls primary hemostasis.
4/2012	The aggressiveness of murine lymphomas selected in vivo by growth rate correlates with galectin-1 expression and response to cyclophosphamide.
6/2011	Novel roles of galectin-1 in hepatocellular carcinoma cell adhesion, polarization, and in vivo tumor growth.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Diego O Croci Research Topics

Disease

27	Neoplasms (Cancer) 01/2022 - 02/2007
8	Inflammation (Inflammations) 06/2021 - 01/2008
7	Hypoxia (Hypoxemia) 01/2022 - 10/2012
5	Neoplasm Metastasis (Metastasis) 11/2020 - 01/2008
2	Glioblastoma (Glioblastoma Multiforme) 12/2021 - 01/2020
2	Colitis 06/2021 - 01/2021
2	Melanoma (Melanoma, Malignant) 11/2020 - 02/2011
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 07/2013
2	Pathologic Processes 10/2015 - 01/2010
2	Breast Neoplasms (Breast Cancer) 02/2013 - 10/2008
2	Thrombosis (Thrombus) 02/2011 - 04/2008
1	Sexually Transmitted Diseases (Sexually Transmitted Disease) 01/2022
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 06/2021
1	Body Weight (Weight, Body) 01/2021
1	Diabetes Mellitus 01/2021
1	Adenocarcinoma 01/2021
1	Insulin Resistance 01/2021
1	Colorectal Neoplasms (Colorectal Cancer) 01/2021
1	Glioma (Gliomas) 01/2020
1	Infections 01/2018
1	Neovascular Glaucoma 05/2017
1	Diabetic Retinopathy (Retinopathy, Diabetic) 05/2017
1	Endometriosis 11/2014
1	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 07/2013
1	Hodgkin Disease (Hodgkin's Disease) 07/2013
1	Multiple Myeloma 07/2013
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/2013
1	Hematologic Neoplasms (Hematological Malignancy) 07/2013
1	Prostatic Neoplasms (Prostate Cancer) 01/2013
1	Disease Progression 01/2013
1	Kaposi Sarcoma (Kaposi's Sarcoma) 10/2012
1	Carcinogenesis 10/2012
1	Thrombasthenia (Glanzmann Thrombasthenia) 07/2012
1	T-Cell Lymphoma (Lymphoma, T Cell) 04/2012
1	Spontaneous Remission 04/2012
1	Lymphoma (Lymphomas) 04/2012
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 07/2011
1	Hepatocellular Carcinoma (Hepatoma) 06/2011
1	Neuroinflammatory Diseases 09/2009
1	Persistent Infection 02/2007

Drug/Important Bio-Agent (IBA)

17	Galectin 1 (LGALS1)IBA 01/2021 - 01/2008
16	LectinsIBA 12/2021 - 02/2007
13	Galectins (Galectin)IBA 01/2022 - 01/2010
13	Polysaccharides (Glycans)IBA 01/2021 - 01/2010
8	1-nitrohydroxyphenyl-N-benzoylalanine (GAL 1)IBA 01/2021 - 06/2011
6	Carrier Proteins (Binding Protein)IBA 01/2021 - 01/2010
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 01/2014
3	LigandsIBA 06/2021 - 01/2016
3	CytokinesIBA 11/2020 - 01/2010
2	Galactose (Galactopyranose)FDA LinkGeneric 10/2021 - 01/2020
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 11/2020
2	Proteins (Proteins, Gene)FDA Link 01/2016 - 10/2008
2	Galectin 3 (LGALS3)IBA 07/2013 - 01/2011
2	Neoplasm Antigens (Tumor Antigens)IBA 01/2010 - 11/2007
1	Interleukin-10 (Interleukin 10)IBA 10/2021
1	Tn antigenIBA 10/2021
1	AntigensIBA 10/2021
1	CarbohydratesIBA 10/2021
1	GlycosyltransferasesIBA 06/2021
1	AcidsIBA 06/2021
1	Granzymes (Granzyme)IBA 01/2021
1	Peptides (Polypeptides)IBA 01/2021
1	Glucose (Dextrose)FDA LinkGeneric 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Dextrans (Dextran)FDA Link 01/2021
1	AzoxymethaneIBA 01/2021
1	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2021
1	Insulin (Novolin)FDA Link 01/2021
1	InterferonsIBA 01/2021
1	Conditioned Culture MediaIBA 11/2020
1	Type I Tumor Necrosis Factor ReceptorsIBA 11/2020
1	CathelicidinsIBA 01/2020
1	Sialic Acid Binding Immunoglobulin-like LectinsIBA 01/2016
1	MucinsIBA 01/2016
1	C-Type Lectins (C-Type Lectin)IBA 01/2016
1	LipidsIBA 01/2016
1	sialosyl-Tn antigenIBA 01/2016
1	ChemokinesIBA 11/2014
1	Vascular Endothelial Growth FactorsIBA 02/2014
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 02/2014
1	AndrogensIBA 01/2013
1	Transcription Factors (Transcription Factor)IBA 10/2012
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2012
1	Blocking AntibodiesIBA 07/2012
1	IntegrinsIBA 07/2012
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2012
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 07/2011
1	Hemoglobins (Hemoglobin)IBA 02/2011
1	matrigelIBA 02/2011
1	CoagulantsIBA 02/2011
1	GlucocorticoidsIBA 01/2011
1	Biological ProductsIBA 01/2010
1	Interleukin-27 (Interleukin 27)IBA 09/2009
1	CaspasesIBA 10/2008
1	Small Interfering RNA (siRNA)IBA 10/2008
1	SurvivinIBA 10/2008
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2008

Therapy/Procedure

10	Therapeutics 01/2022 - 10/2008
3	Immunotherapy 01/2020 - 11/2007
1	Castration 01/2013